SynthesisMedical oncology (Northwood, London, England)2011
Polymorphism of vascular endothelial growth factor -2578C/A with cancer risk: evidence from 11263 subjects.
Synthesis in Medical oncology (Northwood, London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- rs833061 and rs699947 on promoter gene of vascular endothelial growth factor (VEGF) and associated lung cancer susceptibility and survival: a meta-analysis.Medical science monitor : international medical journal of experimental and clinical research · 2014Pooled it
- Vascular endothelial growth factor -634G/C and vascular endothelial growth factor -2578C/A polymorphisms and lung cancer risk: a case-control study and meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Vascular endothelial growth factor (VEGF) -2578C/A and -460C/T gene polymorphisms and lung cancer risk: a meta-analysis involving 11 case-control studies.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Vascular endothelial growth factor (VEGF) gene polymorphisms and risk of head and neck cancer: a meta-analysis involving 2,444 individuals.Molecular biology reports · 2013Pooled it
- Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection.Human genomics · 2013Pooled it
- Interleukin-10 -592C/A, -819C/T and -1082A/G Polymorphisms with Risk of Type 2 Diabetes Mellitus: A HuGE Review and Meta-analysis.PloS one · 2013Pooled it
- Polymorphism of vascular endothelial growth factor -1154G>A (rs1570360) with cancer risk: a meta-analysis of 16 case-control studies.Molecular biology reports · 2012Pooled it
- Meta-analysis of the association between VEGF-634 G>C and risk of malignancy based on 23 case-control studies.Journal of cancer research and clinical oncology · 2011Pooled it
- Lack of association between VEGF -2578C/A polymorphism and risk of colorectal cancer in an Iranian population.Gastroenterology and hepatology from bed to bench · 2020Article
- Genetic Effects of Vascular Endothelial Growth Factor A (VEGF-A) and Its Association with Disease Progression in Breast Cancer Population of Saudi Arabia.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Pharmacogenetics of anticancer monoclonal antibodies.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- The VEGF gene polymorphism impacts brain volume and arterial blood volume.Human brain mapping · 2017Article
- C-reactive protein as a prognostic marker in chronic obstructive pulmonary disease.Experimental and therapeutic medicine · 2014Article
- Polymorphism of VEGF-460C/T associated with the risk and clinical characteristics of lung cancer in Chinese population.Medical oncology (Northwood, London, England) · 2013Article
- Genetic variation in VEGF family genes and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Published data on the association between vascular endothelial growth factor (VEGF) -2578C/A polymorphism and cancer risk is inconclusive. To derive a more precise estimation of association between VEGF -2578C/A polymorphism and the risk of cancer, we performed a meta-analysis of 5415 cancer cases and 5848 controls from 16 published case-control studies. We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association. Our meta-analysis indicated that VEGF -2578C/A polymorphism was associated with the risk of colorectal cancer under homozygote comparison (OR=0.70, 95% CI=0.53-0.92), dominant model (OR=0.72, 95% CI=0.57-0.92), and recessive model (OR=0.82, 95% CI=0.67-1.01), although no evidence of association between VEGF -2578C/A polymorphism and cancer risk was observed as we compared in the pooled analyses (homozygote comparison: OR=0.97, 95% CI=0.81-1.16). More studies are needed to detect VEGF -2578C/A polymorphism and its association with cancer in different ethnic populations incorporated with environmental exposures in the susceptibility of different kinds of cancer.
Indexed as
Identifiers
20635170What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.